The FDA approves a new non-opioid pain pill, Journavx, to treat acute pain in adults. It's a first-generation non-addictive ...

At the Metro Drug Coalition in Knoxville, they see addiction walk through the door every day. According to MDC’s Karen ...

Each year, millions of people in America are prescribed a medicine for acute pain.Now, for the first time in over 20 years, ...

Optum Rx, the pharmacy benefit manager owned by UnitedHealth Group, placed Journavx on some of its commercial formularies in ...

This drug may reduce the risk of addiction to pain medications by decreasing reliance on opioids to reduce pain.

The round, which included more than a dozen investment firms, should give the startup enough cash to get late-stage data for ...

Latigo Biotherapeutics has tapped into investor interest in pain relief medicines with new, non-opioid mechanisms of action, ...

Those who already own VRTX stock may retain it for some time to see if its CF sales continue to rise and how the Journavx and ...

Vertex's Journavx, a new non-opioid pain drug, lands Tier 3 on Optum Rx formularies. Vertex reports $2.91 billion Q4 sales.

Pacira BioSciences, Inc.'s stock is up 33%, backed by a new Exparel patent, growth strategies, and market trends. Click here ...

The medication, called Journavx, was approved in the United States in January. The financial success of new drugs largely depends on how they’re treated by pharmacy benefit managers that ...

As a result, the need for nonaddictive substances is more important than ever before. Enter: Journavx, the first pain medication of its kind approved by the U.S. Food & Drug Administration in 25 ...